Endpoints News: Synthetic DNA player Touchlight scores $60M round to more than triple manufacturing capacity as mRNA gets hot

Kyle Blankenship interviews Karen Fallen, CEO of Touchlight DNA Services, on the growth of genetic medicines and Touchlight’s fundraise and plans to expand its manufacturing facility.

Read more